View Older Stories View More Recent Stories

Jun 6, 2022 10:00AM Vertex Pharma (VRTX) Reports New Data from VX-880 Phase 1/2 Trial
Jun 6, 2022 10:00AM Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions
Jun 2, 2022 10:06AM Vertex Pharma (VRTX), CRISPR Therapeutics (CRSP) Announce Acceptance of Late-Breaking Abstract for CTX001 at EHA
Jun 2, 2022 10:05AM Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
May 31, 2022 08:00AM Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
May 18, 2022 10:33AM Vertex Pharma (VRTX) Appoints Suketu Upadhyay to its Board
May 18, 2022 10:30AM Suketu Upadhyay Elected to Vertex Board of Directors
May 17, 2022 06:45AM Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies
May 17, 2022 06:40AM Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants
May 5, 2022 04:01PM Vertex Reports First Quarter 2022 Financial Results
May 2, 2022 08:33AM Vertex Pharma (VRTX) Issues Update on Phase 1/2 Clinical Trial of VX-880
May 2, 2022 08:30AM Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
Apr 21, 2022 04:05PM Vertex to Announce First Quarter 2022 Financial Results on May 5
Apr 20, 2022 05:45PM Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation
Mar 31, 2022 08:00AM Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain
Mar 26, 2022 05:00PM Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508de
Mar 22, 2022 08:00AM Vertex Pharma (VRTX) Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
Mar 22, 2022 08:00AM Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
Mar 1, 2022 04:05PM Vertex to Present at Cowen’s 42nd Annual Health Care Conference on March 8
Jan 26, 2022 04:01PM Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
Jan 18, 2022 04:05PM Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
Jan 11, 2022 05:26AM Vertex Pharma (VRTX) Announces EU Approval of KAFTRIO in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years
Jan 11, 2022 03:01AM European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years
Jan 4, 2022 04:05PM Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
Dec 1, 2021 07:30AM Vertex Pharma (VRTX) Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
Dec 1, 2021 07:30AM Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
Nov 19, 2021 06:04AM Vertex Pharma (VRTX) Enters Reimbursement Agreement in Spain for KAFTRIO in Combination With Ivacaftor
Nov 19, 2021 06:00AM Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least O
Nov 12, 2021 07:27AM Vertex Pharma (VRTX) Announces Positive CHMP Opinion for KAFTRIO in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
Nov 12, 2021 07:27AM Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
Nov 2, 2021 04:01PM Vertex Reports Third-Quarter 2021 Financial Results
Oct 26, 2021 09:00AM Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
Oct 22, 2021 08:00AM Vertex to Announce Third-Quarter 2021 Financial Results on November 2
Oct 19, 2021 08:04AM Vertex Pharma (VRTX) to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference
Oct 19, 2021 08:00AM Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
Oct 18, 2021 07:30AM Vertex Pharma (VRTX) Reports Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880
Oct 18, 2021 07:30AM Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes
Sep 13, 2021 08:00AM Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th
Aug 26, 2021 07:00AM Vertex Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis
Aug 24, 2021 07:00AM Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies
Aug 4, 2021 08:33AM Vertex Pharma (VRTX) Appoints Stuart A. Arbuckle as Chief Operating Officer
Aug 4, 2021 08:30AM Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer
Jul 29, 2021 04:01PM Vertex Reports Second-Quarter 2021 Financial Results
Jul 28, 2021 08:00AM Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis
Jul 19, 2021 08:00AM Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
Jul 16, 2021 04:01PM Vertex to Announce Second-Quarter 2021 Financial Results on July 29
Jun 11, 2021 03:05AM Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematolo
Jun 9, 2021 08:00AM Vertex Pharma (VRTX) Announces U.S. FDA Approval for TRIKAFTA in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
Jun 9, 2021 08:00AM Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
Jun 9, 2021 08:00AM CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
View More Recent Stories View Older Stories